Clinical Trials Feasibility Risk Assessment and Planning for Success

This report provides the global clinical trial landscape for depression and identifies key analysis of the main features in order to run similar trials successfully.

As the prevalence of depression has increased, the outlook of it has also changed in positive ways. Better support and services for depression as well as the increase of discussing this order has lead to an increase of depression clinical trials. The COVID-19 pandemic has played a major role in that.

Key Highlights

COVID-19 pandemic has changed the landscape of depression clinical trials
Depression clinical trials are being ran all around the world, with North America having the most.
Top sponsors for depression trials are Eli Lilly and Massachusetts General Hospital.
The important of eliminating delays in depression clinical trials.
It is essential to select the right trial design, such as sites and investigators.

Scope

This report provides a review of global depression clinical trials derived from the the Clinical Trials Database and Feasibility Planner. The aim of this report is to provide analyses of these trials, coupled with analyses of what to expect when running a similar trial.

Reasons to Buy

Identifies and analyses depression clinical trials by multiple trial designs, such as trial start year, phase and virtual components.
Examines the effect of COVID-19 on depression trials
Gives reason for certain trends seen in depression trials
Uses the Publisher's Feasibility Planner to help to improve trial planning
Comparison of enrollment parameters for different trials to an industry average
Provides analysis of best suited clinical trial sites and investigators for depression trials

1 Table and Figures

List of Tables
List of Figures

2 Executive Summary

3 Introduction

Report Scope
Methodology

4 Global Depression Clinical Trial Landscape

2021 Was the Leading Year in Depression Clinical Trials
Phase I Has Dominated Depression Trials Since 2020
Single-Country Tops Multinational for Depression Trials
North America Has the Most Depression Clinical Trials
Non-industry Sponsors Lead Overall in Depression Trials
Eli Lilly Is the Top Industry Sponsor
Massachusetts General Hospital Tops Non-industry Sponsors
Phase IV Has the Longest Enrollment Period and Trial Duration
Two-Thirds of Depression Trials Have Achieved Endpoint Status
Decentralized Clinical Trial Used More in Depression Trials Due to the COVID-19 Pandemic
Mobile Healthcare and Telemedicine Used the Most in Decentralized Clinical Trials

5 Feasibility Planner - A Depression Case Study

Low Accrual Rate Is the Top Reason for Trial Termination in All Phases
Enrollment Rate Higher in Industry Average Compared to Five Trials
Number of Subjects and Sites Comparison of Five Trials to Industry Average
US Also Has the Most Recommended Sites for Depression Trials
Pennsylvania, US Is the Top Choice for Depression Clinical Trial Sites
US Has the Most Recommended Investigators for Depression Trials

6 Key Findings

7 Appendix

Abbreviations
About the Authors
About the Publisher
Contact the Publisher

List of Tables

Table 1: Average Distance Travelled Between Top Five Sites for Depression Trials to the Top Five Sites by Disease Prevalence in the US

List of Figures

Figure 1: Number of Depression Clinical Trials, by Trial Start Year (2015-23)
Figure 2: Number of Depression Clinical Trials, by Trial Start Year and Phase
Figure 3: Number of Depression Clinical Trials by Phase, Single-Country Versus Multinational
Figure 4: Number of Depression Clinical Trials by Region and Phase
Figure 5: Number of Depression Clinical Trials by Phase, Industry Versus Non-industry
Figure 6: Depression Clinical Trials, by Top 10 Industry Sponsors
Figure 7: Depression Clinical Trials, by Top 10 Non-industry Sponsors
Figure 8: Projected Timelines for Depression Clinical Trials, by Phase
Figure 9: Endpoint Status for Depression Clinical Trials, by Phase
Figure 10: Number of Depression Trials Using Decentralized Virtual Components
Figures 11-12: Number of Depression Clinical Trials, by Virtual Components
Figure 13: Number of Depression Clinical Trials, by Trial Termination and Phase
Figure 14: Enrollment Rate Comparison
Figure 15: Number of Subjects and Sites Comparison
Figure 16: Top Recommended Sites for Depression Clinical Trials
Figure 17: Distance in Hours Between Top Five Sites for Depression Trials to the Top Five Sites by Disease Prevalence in the US
Figure 18: Top Recommended Investigator for Depression Clinical Trials

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Eli Lilly
Massachusetts General Hospital
CVS
Johnson & Johnson
GlaxoSmithKline

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€690EUR$695USD£574GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€1035EUR$1,042USD£861GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€1381EUR$1,390USD£1,148GBP

Clinical Trials Feasibility Risk Assessment and Planning for Success - A Depression Case Study

Key Highlights

Scope

Reasons to Buy

Table of Contents

Companies Mentioned (Partial List)

Key Highlights

Scope

Reasons to Buy

Table of Contents

Companies Mentioned (Partial List)

Related Topics

Related Reports

Clinical Trials: Psychedelic Therapeutics

Innovative AI-enabled Clinical Trial Companies: Strategic Profiling and Growth Opportunities

Clinical Trial Support Services Market by Service, Phase, Study Design, Indication, Sponsor - Global Forecast 2025-2030

Plaque Psoriasis (Psoriasis Vulgaris) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update

Virtual Clinical Trials - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029